

REMARKS/ARGUMENTS

Claims 91-115 are pending in this application. Claims 102, 103 and 105-110 are rejected. Claims 104 and 111-114 are objected to. Claims 91-101 and 115 are allowable. The method of use claims have been rejoined, since the compound claims, 91-101, were found to be allowable.

Claims 102, 103 and 105-110 are rejected under 35 U.S.C. 112, first paragraph, on the ground that the specification, while being enabling for methods for treating specific diseases, such as migraine, asthma, dementia, epilepsy, etc., does not reasonably provide enablement for all diseases affected by the inhibition of histamine H₃ receptor activity. The Examiner has suggested that applicants incorporate the diseases recited in claims 104 and 113 into the claims reciting only the inhibition of the "histamine H₃ receptor".

By the present amendment claim 104 has been canceled and the subject matter of claim 104 has been incorporated into claim 103. Claims 105-110 have been canceled. Claim 102 is drawn to a method of inhibiting histamine H₃ receptor activity without reference to a disease or condition. It is submitted that there is no need to incorporate the diseases recited in claim 104 into claim 102.

Reconsideration of the rejection of claim 102 and 103 is courteously requested.

Claims 104 and 111-114 are objected to for depending on a rejected base claim. As indicated above, claim 104 has been canceled and the disease states set forth in claim 104 have been incorporated into claim 103. Claims 111-114 each refer to claims 91 or 99. As indicated by the Examiner, claims 91 and 99 have been found to be allowable. Claims 111-114, therefore, are not dependent on a rejected base claim and should be allowable. However, in view of the fact that the Examiner has suggested that the claims should refer to claims only

reciting the inhibition of the histamine H₃ receptor, applicants have made claims 111-114 depend on claim 103 which is drawn to a method of treating diseases modulated by the histamine H₃ receptor.

In view of the above discussion and the amendments herein being made to the claims, it is believed that all of the outstanding objections and rejections have been removed.

Applicants respectfully request that a timely Notice of Allowance be issued in this application.

Respectfully submitted,

/ John W. Harbour/
John W. Harbour
Reg. No. 31,365
Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Drive
New Brunswick, NJ 08933
(732) 524-2169
Date: December 7, 2005